Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT) (BISCIT)
Secondary Sclerosing Cholangitis
About this trial
This is an interventional treatment trial for Secondary Sclerosing Cholangitis focused on measuring biliary intervention, endoscopic therapy, endoscopic retrograde cholangiography
Eligibility Criteria
Inclusion Criteria:
Patients have to fulfill all of the following inclusion criteria to be eligible for participation in this study:
- Men, women*, inter/divers, age ≥18 and ≤ 80 years (conscious or unconscious patients may be included)
- Signed written informed consent obtained by patient or legal representative in case of unconscious patient
- Willingness to comply with treatment and follow-up procedures
- Suspected SSC-CIP = episode of critical illness and intensive care unit treatment > 3 days within last 12 months
- SSC-CIP is confirmed by ERC, (if the first ERC is performed at baseline, the patient may be considered as screening failure if the diagnosis is not confirmed)
- Elevation of bilirubin ≥ 2.5 upper limit of normal (ULN) at Screening
- Elevation of alkaline phosphatase (AP) or gamma-glutamyl-transferase (GGT) > 2.5 ULN or elevation of both at Screening
*Women without childbearing potential defined as follows:
- at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
- hysterectomy or uterine agenesis or
- ≥ 50 years and in postmenopausal state > 1 year or
< 50 years and in postmenopausal state > 1 year with serum Follicle Stimulating Hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or
*Women of childbearing potential:
- who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or
- who have sexual relationships with female partners only and/or with sterile male partners or
- who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception (failure rate of < 1% per year) from the time of screening until end of the clinical trial.
Exclusion Criteria:
- Patient is too unstable to undergo ERC
- Inclusion in any other intervention trial within the last 30 days
- Pregnancy or lactation period
Sites / Locations
- Hannover Medical School
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
interventional
control
The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.
The control group receives non-interventional standard of care.